DUBLIN–(BUSINESS WIRE)–The “Angelman Syndrome Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical and forecasted Angelman Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Angelman Syndrome Understanding
The Angelman Syndrome epidemiology report gives a thorough understanding of the Angelman Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Angelman Syndrome in the US, Europe, and Japan. The report covers the detailed information of the Angelman Syndrome epidemiology scenario in seven major countries (US, EU5, and Japan).
Angelman Syndrome Epidemiology Perspective by the publisher
The Angelman Syndrome epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Angelman Syndrome epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Angelman Syndrome epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Angelman Syndrome Detailed Epidemiology Segmentation
The Angelman Syndrome epidemiology covered in the report provides historical as well as forecasted Angelman Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
The Angelman Syndrome report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Scope of the Report
- The Angelman Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Angelman Syndrome Epidemiology Report and Model provide an overview of the global trends of Angelman Syndrome in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight into the historical and forecasted patient pool of Angelman Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps recognize the growth opportunities in the 7MM for the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Angelman Syndrome
- The report provides the segmentation of the Angelman Syndrome epidemiology
Report Highlights
- 11-year Forecast of Angelman Syndrome epidemiology
- 7MM Coverage
- Prevalent and Diagnosed Cases of Angelman Syndrome
- Cases of Angelman Syndrome by Mutation Types
- Angelman Syndrome Cases associated with Clinical Manifestations
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global Angelman Syndrome market
- Quantify patient populations in the global Angelman Syndrome market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Angelman Syndrome therapeutics in each of the markets covered
- Understand the magnitude of Angelman Syndrome population by its epidemiology
- The Angelman Syndrome Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Topics Covered:
1. Key Insights
2. Executive Summary of Angelman Syndrome
3. SWOT Analysis for Angelman Syndrome
4. Disease Background and Overview
4.1. Introduction
4.2. Cause
4.3. Signs and Symptoms
4.4. Related Disorders and Differential Diagnosis
4.5. Complications
4.6. Genetics of Angelman syndrome
4.7. Molecular Genetic Pathogenesis
4.8. Diagnosis
4.9. Clinical criteria for diagnosis
4.10. Disease History and Medical Conditions
4.11. Diagnostic Algorithm
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. 7MM Total Prevalent Patient Population of Angelman syndrome
6. Country Wise-Epidemiology of Angelman syndrome
6.1. The United States
6.2. EU5
6.3. Japan
7. Treatment and Management of Angelman syndrome
7.1. Recommendations for the management of Angelman Syndrome
7.2. Future treatment options for Angelman Syndrome
7.2.1. Gene Therapy
7.2.2. Topoisomerase Inhibitors
7.2.3. Minocycline
7.2.4. Cannabidiol (CBD)
7.2.5. Protein Phosphatase 2A (PP2A) Inhibitor
8. Unmet Needs
9. Organizations contributing toward Angelman Syndrome
10. KOL’s Views: Angelman Syndrome
11. Patient Journey
12. Journey toward a Diagnosis: Diagnosing a Rare form of Angelman Syndrome
13. Case Reports
14. Appendix
15. Capabilities
16. Disclaimer
17. About the Publisher
For more information about this report visit https://www.researchandmarkets.com/r/xkk0d4
